ZeymerU,RaoSV,MontalescotG.,,2016,Anticoagulation in coronary intervention,Eur Heart J,37,3376-85
SmithSC,FeldmanTE,HirshfeldJW,JacobsAK,KernMJ,KingSB,,2006,update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention),J Am Coll Cardiol,47,e1-121
WijnsW,KolhP,DanchinN,Di MarioC,FalkV,FolliguetT,,2010,Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS),Eur Heart J,31,2501-55
StegPG,JollySS,MehtaSR,AfzalR,XavierD,RupprechtHJ,,2010,Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial,J Am Med Assoc,304,1339-49
BrenerSJ,MoliternoDJ,LincoffAM,SteinhublSR,WolskiKE,TopolEJ,,2004,Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention,Circulation,110,994-8
De CaterinaR,HustedS,WallentinL,AgnelliG,BachmannF,BaigentC,,2007,Anticoagulants in heart disease: current status and perspectives,Eur Heart J,28,880-913
WindeckerS,KolhP,AlfonsoF,ColletJP,CremerJ,FalkV,,2014,ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).,,,-
AlamS,NaqviS,GauharS. Product,Management,,2009,Efficacy Evaluation of an Anti-Coagulant Enoxapari (Clexane,Pakistan; Oman Med J,24,264-8
SilvainJ,BeyguiF,AnkriA,Bellemain-AppaixA,PenaA,BarthelemyO,,2010,Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test,J Am Coll Cardiol,55,617-25
MontalescotG,ColletJP,TanguyML,AnkriA,PayotL,DumaineR,,2004,Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin,Circulation,110,392-8
MontalescotG,ZeymerU,SilvainJ,BoulangerB,CohenM,GoldsteinP,,2011,Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL Trial,Lancet,378,693-703
DiezJG,,2008,Practical issues on the use of enoxaparin in elective and emergent percutaneous coronary intervention,J Invasive Cardiol,20,482-9
MarsoSP,AminAP,HouseJA,KennedyKF,SpertusJA,RaoSV,,2010,Association Between Use of Bleeding Avoidance Strategies and Risk of Periprocedural Bleeding Among Patients Undergoing Percutaneous Coronary Intervention,J Am Med Assoc,303,2156-64
ChhatriwallaAK,AminAP,KennedyKF,HouseJA,CohenDJ,RaoSV,,2013,Association Between Bleeding Events and In-hospital Mortality After Percutaneous Coronary Intervention,J Am Med Assoc,309,1022-9
YusafS,HawkenS,OupuuS,DansT,AvezumA,LanasF,,2004,Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case control study,Lancet,364,937-52
KhanMA,HassanM,HafizullahM.,,2006,Coronary artery disease, is it more frequently affecting younger age group and women?,Pak Heart J,39,17-21